ERBB2 and neoplasm: Among all tumor subtypes, HR+/HER2– PrBC showed significantly higher TILs compared to HR+/HER2– EOBC (n = 41, 93.2% vs. 45, 76.3%; p = 0.022, Chi-square test), as shown in Table 2.